Outlook Therapeutics stock slumps after FDA rejects ONS-5010
Published on 11/17/2026 at 22:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory setback hits lead program
- The FDA rejected Outlook Therapeutics' marketing application for ONS-5010, its lead ophthalmic drug.
- The treatment targets wet age-related macular degeneration, making the decision central to the company's US commercialization path.
On Tuesday, November 17, 2026, the FDA rejected Outlook Therapeutics' marketing application for ONS-5010, the company's lead treatment for wet age-related macular degeneration. Pharmaphorum reported that the regulatory decision sent the shares sharply lower.
FDA decision changes the outlook
ONS-5010 is an ophthalmic formulation aimed at treating wet AMD. The rejection affects the US regulatory path for Outlook Therapeutics' lead program and raises the importance of any subsequent company response or revised application.
For investors, the decision puts the company's commercial plans under renewed regulatory pressure. The outcome also shifts attention toward the next formal update from Outlook Therapeutics on the application, the drug's development path and its plans for the US market.
Outlook Therapeutics
- Company: Outlook Therapeutics, Inc.
- Ticker: OTLK
- ISIN: US69012T3059
- Lead program: ONS-5010 for wet age-related macular degeneration
The broader US market context is covered by the S&P 500 market reports.
